Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Basilea Pharmaceutica AG's oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study


Monday, 2 Jun 2014 01:15am EDT 

Basilea Pharmaceutica AG:Says that phase 1 study results of its investigational oncology drug, BAL101553, were presented at American Society of Clinical Oncology (ASCO) annual meeting in Chicago, U.S.A.Maximum tolerated dose (MTD) was determined and results indicated first evidence of clinical antitumor activity.BAL101553 is an intravenous and oral microtubule-targeting agent (MTA.Previous preclinical studies demonstrated that investigational drug has potent anti-cancer activity in tumor models refractory to conventional MTAs.It was shown to arrest tumor cell proliferation and to induce tumor cell death through a destabilizing effect on microtubules which are an intracellular network essential for cell division. In addition, tumor-specific vascular disruption activity was observed in preclinical cancer models.Currently reported phase 1 open-label, dose-escalation study included adult patients with advanced solid tumors who had failed standard therapy.Study investigated safety and tolerability of intravenous BAL101553 and evaluated pharmacokinetics, pharmacodynamics and antitumor activity.